AdventHealth Hematology and Oncology

Orlando, Florida 32804

2 studies enrolling now · 7 studies all time

What they study most

Biliary Tract Cancer, Breast Cancer, Carcinoma, Small Cell Lung, ER-positive Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Locally Advanced Breast Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC)

Studies at this site

• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer — Recruiting now
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Running, not enrolling
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Running, not enrolling
• RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer — Stopped early